No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Thursday, October 9, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Startups

Inductive Bio Secures $25M Series A to Transform Drug Discovery with its Collaborative AI Platform – AlleyWatch

by TheAdviserMagazine
5 months ago
in Startups
Reading Time: 7 mins read
A A
Inductive Bio Secures M Series A to Transform Drug Discovery with its Collaborative AI Platform – AlleyWatch
Share on FacebookShare on TwitterShare on LInkedIn


In the complex and costly world of pharmaceutical development, the process of drug discovery remains one of the most significant bottlenecks, with scientists often describing compound optimization as a frustrating “whack-a-mole” game where fixing one molecular issue creates multiple new problems. Traditional approaches require making thousands of molecules over years, consuming millions of dollars with no guarantee of success. Inductive Bio has developed a collaborative AI platform that dramatically accelerates compound optimization by predicting how molecules will behave in the human body before they’re synthesized in a lab. Through their pre-competitive data consortium, multiple pharmaceutical companies share anonymized data in a secure environment, creating a foundation that allows AI models to learn from thousands of real-world drug programs rather than limited datasets from individual companies. AlleyWatch sat down with Inductive Bio CEO and Founder Josh Haimson to learn more about the business, its future plans, and recent funding round that brings the company’s total funding raised to $29.3M.

Who were your investors and how much did you raise?

We raised $25M in Series A financing led by Obvious Ventures with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, Section 32, Character, and Amino Collective, alongside several angel investors.

Tell us about the product or service that Inductive Bio offers.

Inductive Bio has developed a collaborative AI platform that dramatically accelerates compound optimization, a critical and time-consuming step in developing new therapeutics. Our platform combines purpose-built machine learning models with intuitive design software to help scientists efficiently navigate chemical space and design higher-quality drug candidates. These tools predict small-molecule ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity) — the critical factors that determine whether a drug will work in the human body.

In simple terms, our platform allows chemists to design molecules and get immediate AI predictions about how they would behave in the human body, rather than spending a month and thousands of dollars making each molecule in a lab. This helps scientists focus their resources on the most promising compounds, significantly speeding up the development of potentially life-saving medicines.

What inspired the start of Inductive Bio?

After our experience at Flatiron Health analyzing cancer patient data, my cofounder Ben Birnbaum and I wanted to address challenges earlier in the drug development process. We discovered that finding the right drug molecule is often a major bottleneck.

Chemists described their process as a frustrating game of “whack-a-mole” — when they fix one issue with a molecule, two other issues pop up. This traditional approach requires making thousands of molecules over years, costing millions of dollars. We saw an opportunity to use AI to make this process faster and to help scientists design higher quality drug candidates by predicting which molecules would work best before making them in the lab.

How is Inductive Bio different?

What makes us unique is that collaborative approach. We’ve created a “pre-competitive data consortium” where multiple pharmaceutical and biotech companies share certain anonymized data in a secure environment. This allows our AI to learn from thousands of real-world drug programs rather than just a limited dataset from one company.

Think of it like Waze for drug discovery — everyone contributes data about traffic conditions, and in return, everyone gets better navigation. Our approach was validated in the recent Polaris ADMET competition, where our model placed first among 39 participants from leading drug discovery companies and academic groups.

What market does Inductive Bio target and how big is it?

We work with biotech and pharmaceutical companies developing small-molecule drugs — typically the kind that can be taken as pills — across many disease areas, including brain disorders, cancer, and inflammatory conditions.

Small molecules represent the majority of drugs in development today. We focused here because there was a significant opportunity to improve efficiency in an area that affects many patients and represents billions in R&D spending annually. 

What’s your business model?

As mentioned, we operate on a collaborative pre-competitive consortium model. What this means for our business is that we generate revenue through software licensing and scientific collaboration agreements. Partners pay to access our AI-powered platform that helps them design better drugs faster, while also contributing anonymized data that strengthens the system for everyone.

Unlike many AI drug discovery companies, we don’t develop our own drugs. Instead, we focus exclusively on being a technology partner that accelerates drug discovery across the entire industry. This approach has proven successful — our revenue increased significantly last year as we’ve expanded to support dozens of active drug programs across many therapeutic areas.

How are you preparing for a potential economic slowdown?

Interestingly, economic uncertainty often increases demand for our services, as companies face pressure to develop drugs more efficiently with fewer resources.

Our technology reduces risk in the drug development process — if companies can make fewer unsuccessful molecules and focus on compounds more likely to succeed, they save both time and money. This value proposition becomes even more compelling in challenging economic times.

What was the funding process like?

It came together faster than expected. I had braced myself for a long, challenging market, but I think the problem we’re tackling of optimizing chemistry before you get into the clinic and really accelerating those timelines, combined with the traction we’ve been seeing in the market, really convinced investors and it came together very quickly. 

What are the biggest challenges that you faced while raising capital?

While our Series A came together relatively quickly, we faced the challenge of differentiating ourselves in a landscape where AI drug discovery has seen its share of hype. We needed to demonstrate that our approach wasn’t just another AI platform making ambitious claims, but one that delivers measurable value to partners today.

Another challenge was explaining our business model to investors more familiar with either traditional biotech or enterprise SaaS. We had to clearly articulate how our approach creates significant value for our partners and in turn allows us to build a high-growth business. Ultimately, these challenges pushed us to refine our story and focus on showing real results and revenue generation.

What factors about your business led your investors to write the check?

Our investors were impressed that we’ve moved beyond the hype often surrounding AI in healthcare to deliver measurable results. They recognized our approach is already changing how drugs are developed, with the potential to fundamentally transform the economics and pace of drug development.

Our technology meaningfully reduces the number of unsuccessful molecules that need to be made and helps companies reach key milestones faster. This creates both time and cost savings for our partners while helping design a better drug at the end of the day. This results in a sustainable business model with clear return on investment. The fact that we’ve demonstrated this value across dozens of active drug programs, rather than just promising future potential, was particularly compelling to investors.

What are the milestones you plan to achieve in the next six months?

We’re focused on growing our team (currently 10 people, soon to be 12), expanding our platform to more pharmaceutical companies, advancing our AI capabilities, and bringing academic research groups into our consortium. The more diverse our data becomes, the more powerful our predictions will be for all partners.

What advice can you offer companies in New York that do not have a fresh injection of capital in the bank? 

Focus relentlessly on solving a real problem that customers are willing to pay for. Through conversations with potential customers and small consulting engagements, we validated that there was genuine demand for our solution before building our platform.

At the earliest stages, make sure you’re solving the right problem for the right person in the right way. Everything else — including fundraising — becomes easier once you’ve proven you can deliver real value.

Where do you see the company going in the near term?

Our goal is to make our platform the industry standard that scientists use to design better drugs. We’re talking to multiple potential clients weekly and hiring rapidly. Long-term, we’d like to grow into a public company that accelerates drug discovery across the entire industry, ultimately helping patients get better treatments sooner.

What’s your favorite spring destination in and around the city?

Prospect Park! I live just around the corner, and it’s amazing to watch it come alive — flowers blooming, people picnicking, dancing, biking, and dogs and kids running wild across the fields. I always check the Celebrate Brooklyn concert lineup and try to catch as many shows as I can.Daily Funding Report /need a newsletter block for alleywatch

I’ll create a newsletter block for AlleyWatch that matches the provided style guide. Based on the documentation, the newsletter block should follow a specific structure with the correct URLs for AlleyWatch.

AlleyWatch Newsletter Signup BlockInteractive artifactHere’s the newsletter signup block for AlleyWatch that matches the style guide from your documentation. The HTML includes:

The correct URL for AlleyWatch’s email signup (https://email.alleywatch.com)The proper image URL from the AlleyWatch websiteThe specified styling with centered text, proper margins and paddingThe “NYC Tech” branding in t

NYC Tech Daily Email

You are seconds away from signing up for the hottest list in NYC Tech!

Sign up today



Source link

Tags: 25MAlleyWatchBIOCollaborativeDiscoverydrugInductiveplatformsecuresSeriestransform
ShareTweetShare
Previous Post

Bank of America Cards Sweeten Introductory Offers for New Holders

Next Post

What Is the Income Limit for Marketplace Insurance?

Related Posts

edit post
Duolingo says it will ‘never’ open a San Francisco office

Duolingo says it will ‘never’ open a San Francisco office

by TheAdviserMagazine
October 9, 2025
0

Duolingo is saying no, non, nein, and nyet to San Francisco. The language learning app is headquartered in Pittsburgh, which...

edit post
Google Autocomplete: How a Few Words Shape Entire Reputations

Google Autocomplete: How a Few Words Shape Entire Reputations

by TheAdviserMagazine
October 9, 2025
0

Type a few letters into Google, and the search bar finishes your thought. For most people, it’s a time-saver. But...

edit post
Germany’s industrial AI startup findIQ launches US expansion after €3.4M Seed funding

Germany’s industrial AI startup findIQ launches US expansion after €3.4M Seed funding

by TheAdviserMagazine
October 9, 2025
0

Herford, Germany-based findIQ, a company that specialises in an AI-based knowledge platform, announced its expansion into the US market with...

edit post
Here’s what it’s really like to appear on billionaire VC Tim Draper’s ‘Meet the Drapers’ pitch show

Here’s what it’s really like to appear on billionaire VC Tim Draper’s ‘Meet the Drapers’ pitch show

by TheAdviserMagazine
October 8, 2025
0

There was barely a breeze on the roof of the MCM studios building in Manhattan last week as six entrepreneurs...

edit post
Amsterdam’s Endeit Capital backs Stockholm-based Eir Insurance in €20M round: Know more 

Amsterdam’s Endeit Capital backs Stockholm-based Eir Insurance in €20M round: Know more 

by TheAdviserMagazine
October 8, 2025
0

Stockholm-based Eir Insurance,  a fully licensed B2B2X white-label insurance company, has secured €20M in a growth funding round led by...

edit post
Attracting Top Talent with Employee Benefits

Attracting Top Talent with Employee Benefits

by TheAdviserMagazine
October 8, 2025
0

The talent acquisition landscape has fundamentally shifted. Competitive salaries, once the primary battleground for securing star performers, no longer guarantee...

Next Post
edit post
What Is the Income Limit for Marketplace Insurance?

What Is the Income Limit for Marketplace Insurance?

edit post
DNB Bank expands tie up with Infosys to expedite IT modernisation

DNB Bank expands tie up with Infosys to expedite IT modernisation

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
Tips to Apply for Mental Health SSDI Without Therapy

Tips to Apply for Mental Health SSDI Without Therapy

September 19, 2025
edit post
Asian shares: Asian shares dip at open, gold trades below ,000

Asian shares: Asian shares dip at open, gold trades below $4,000

0
edit post
Former Fed Governor Larry Lindsey withdraws name for Fed chair

Former Fed Governor Larry Lindsey withdraws name for Fed chair

0
edit post
Negotiated Prices Take Effect for Ten Drugs in 2026

Negotiated Prices Take Effect for Ten Drugs in 2026

0
edit post
Levi Strauss signals 6% organic net revenue growth for 2025 while raising EPS outlook (NYSE:LEVI)

Levi Strauss signals 6% organic net revenue growth for 2025 while raising EPS outlook (NYSE:LEVI)

0
edit post
A practical roadmap for indirect tax leaders

A practical roadmap for indirect tax leaders

0
edit post
The Debt Ceiling: A Nation Divided and Indebted Cannot Stand

The Debt Ceiling: A Nation Divided and Indebted Cannot Stand

0
edit post
Asian shares: Asian shares dip at open, gold trades below ,000

Asian shares: Asian shares dip at open, gold trades below $4,000

October 9, 2025
edit post
Levi Strauss signals 6% organic net revenue growth for 2025 while raising EPS outlook (NYSE:LEVI)

Levi Strauss signals 6% organic net revenue growth for 2025 while raising EPS outlook (NYSE:LEVI)

October 9, 2025
edit post
Former Fed Governor Larry Lindsey withdraws name for Fed chair

Former Fed Governor Larry Lindsey withdraws name for Fed chair

October 9, 2025
edit post
New York AG Letitia James charged in mortgage fraud investigation

New York AG Letitia James charged in mortgage fraud investigation

October 9, 2025
edit post
How RIAs use LinkedIn and other social media

How RIAs use LinkedIn and other social media

October 9, 2025
edit post
Biogen – BIIB: Leqembi erhält Zulassungen in China & Australien!

Biogen – BIIB: Leqembi erhält Zulassungen in China & Australien!

October 9, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Asian shares: Asian shares dip at open, gold trades below $4,000
  • Levi Strauss signals 6% organic net revenue growth for 2025 while raising EPS outlook (NYSE:LEVI)
  • Former Fed Governor Larry Lindsey withdraws name for Fed chair
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.